Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 11,226,000 | 11,337,000 | 11,406,000 | 11,218,000 | 11,887,000 |
| Cost of Goods | 2,876,000 | 2,566,000 | 2,593,000 | 2,353,000 | 2,720,000 |
| Gross Profit | 8,350,000 | 8,771,000 | 8,813,000 | 8,865,000 | 9,167,000 |
| Operating Expenses | 6,491,000 | 6,001,000 | 6,954,000 | 6,656,000 | 7,209,000 |
| Operating Income | 1,859,000 | 2,770,000 | 1,859,000 | 2,209,000 | 1,958,000 |
| Pre-tax Income | 1,859,000 | 2,770,000 | 1,859,000 | 2,209,000 | 1,958,000 |
| Income Tax | -218,000 | 503,000 | -166,000 | 601,000 | 529,000 |
| Net Income Continuous | 2,077,000 | 2,267,000 | 2,025,000 | 1,608,000 | 1,429,000 |
| Minority Interests | 4,000 | 5,000 | 3,000 | 2,000 | 8,000 |
| Net Income | $2,073,000 | $2,262,000 | $2,022,000 | $1,606,000 | $1,421,000 |
| EPS Basic Total Ops | 0.99 | 1.08 | 0.95 | 0.75 | 0.67 |
| EPS Basic Continuous Ops | 0.99 | 1.08 | 0.96 | 0.75 | 0.67 |
| EPS Diluted Total Ops | 0.99 | 1.07 | 0.95 | 0.75 | 0.66 |
| EPS Diluted Continuous Ops | 0.99 | 1.07 | 0.95 | 0.75 | 0.67 |
| EPS Diluted Before Non-Recurring Items | 1.75 | 2.05 | 1.82 | N/A | N/A |
| EBITDA(a) | $4,291,000 | $5,199,000 | $4,380,000 | $4,797,000 | $4,541,000 |